Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026
Funding remains necessary to advance varoglutamstat into a Phase 2b study in advanced diabetic kidney disease.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vivoryon Therapeutics (VVY) will publish its third-quarter 2026 financial results and a business update on November 5, 2026. The results cover the period ended September 30, 2026, and the update will include revised cash runway guidance.
The company said its priority remains securing funding to advance varoglutamstat into a Phase 2b study in advanced diabetic kidney disease. It reported progress in partnering efforts and is in advanced negotiations with different parties for a kidney-disease partnership. Vivoryon has also implemented additional cost-saving measures aimed at preserving financial resources while pursuing partnering activities.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointVaroglutamstat partnering efforts have progressed to advanced negotiations with different parties.
- Minor pointAdditional cost-saving measures implemented aim to preserve financial resources during partnering activities.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Varoglutamstat's planned Phase 2b study remains dependent on securing necessary funding.
- Moderate pointThe kidney-disease partnership remains under negotiation, rather than secured.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results
on November 5, 2026
Halle (Saale) / Munich, Germany, October 30, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its third quarter financial results for the period ended September 30, 2026 on Thursday, November 5, 2026.
As part of its third quarter financial results, Vivoryon will provide a business update, including updated cash runway guidance. The Company’s key strategic priority remains securing the funding necessary to advance varoglutamstat into a Phase 2b clinical study in patients with advanced diabetic kidney disease, with the aim of confirming the compelling data observed in the VIVIAD and VIVA-MIND studies.
Vivoryon has made further progress in its strategic partnering efforts and is engaged in advanced negotiations with different parties towards securing a partnership for varoglutamstat in kidney disease. In parallel, Vivoryon has implemented additional cost-saving measures aimed at preserving its financial resources while pursuing its strategic partnering activities.
All ongoing negotiations and potential investments remain subject to the customary risks and uncertainties associated with such processes, and there can be no assurance that any transaction or investment will materialize.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Vivoryon (VVY) report its Q3 2026 financial results?
Vivoryon will publish its third-quarter financial results on November 5, 2026, covering the period ended September 30, 2026. The accompanying business update will include updated cash runway guidance.
What is the status of Vivoryon's varoglutamstat partnership talks?
Vivoryon is in advanced negotiations with different parties toward securing a partnership for varoglutamstat in kidney disease. Its stated priority remains obtaining the funding needed to advance the drug into a Phase 2b study in patients with advanced diabetic kidney disease.